-
公开(公告)号：US20230019286A1
公开(公告)日：2023-01-19
申请号：US17240351
申请日：2021-04-26
Applicant: Bioverativ Therapeutics Inc.
Inventor： Volker SCHELLENBERGER , Pei-Yun CHANG , Fatbardha VARFAJ , John KULMAN , Tongyao LIU , Garabet G. TOBY , Haiyan JIANG , Robert PETERS , Deping WANG , Baisong MEI , Joshua SILVERMAN , Chia-Wei WANG , Benjamin SPINK , Nathan GEETHING
IPC: C07K14/755 , C07K14/00
Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
-
公开(公告)号：US20220056108A1
公开(公告)日：2022-02-24
申请号：US17358142
申请日：2021-06-25
Applicant: Bioverativ Therapeutics Inc.
Inventor： Ekta Seth CHHABRA , Tongyao LIU , Pei-yun CHANG , Robert T. PETERS , John KULMAN , Haiyan JIANG
Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
-
公开(公告)号：US20210032616A1
公开(公告)日：2021-02-04
申请号：US16920970
申请日：2020-07-06
Applicant: Bioverativ Therapeutics Inc.
Inventor： Zhiqian LIU , Arjan VAN DER FLIER , David R. LIGHT , Ekta Seth CHHABRA , Tongyao LIU , Robert T. PETERS , John KULMAN , Ayman ISMAIL
Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.
-
公开(公告)号：US20190315835A1
公开(公告)日：2019-10-17
申请号：US16369820
申请日：2019-03-29
Applicant: Bioverativ Therapeutics Inc.
Inventor： Volker SCHELLENBERGER , Pei-Yun CHANG , Fatbardha VARFAJ , John KULMAN , Tongyao LIU , Garabet G. TOBY , Haiyan JIANG , Robert PETERS , Deping WANG , Baisong MEI , Joshua SILVERMAN , Chia-Wei WANG , Benjamin SPINK , Nathan GEETHING
IPC: C07K14/755 , C07K14/00
Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
-
-
-
Search Results
14
records
(took 0.027 seconds)
